• Study Resource
  • Explore
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Biological Components of Substance Abuse and Addiction (Part 3 of 8)
Biological Components of Substance Abuse and Addiction (Part 3 of 8)

... ubstance abuse and addiction are complex phenomena that defy simple explanation or description. A tangled interaction of factors contributes to an individual’s seeking out, using, and perhaps subsequently abusing drugs. Since more individuals experiment with drugs than eventually develop substance a ...
general_pharmacology
general_pharmacology

... triple distilled and pyrogen free (pyrogen: are bacterial products which cause a rise in body and rigors when injected).  The glass container should be neutral as not react with drug.  The contents are usually liquid but may be in powder form to dissolve immediately before use.  They may be dispe ...
Appendix - LWW.com
Appendix - LWW.com

... warning for the drug label. The black box warning is a special format on the official FDAapproved manufacturer's product label calling attention to the risk of serious or life-threatening events. If conditional approval had been given to this new and potentially better class of antidepressants, an o ...
drug master file: [18f]fdg
drug master file: [18f]fdg

... to batch. b. Sterility The product is delivered in a sterile multi-dose vial. No addition of liquid or aliquotting to another storage container is permitted. Individual doses are removed from this vial using aseptic techniques and only by trained pharmacy staff or nuclear medicine technicians. Durin ...
Dr. Brian Feagan
Dr. Brian Feagan

... – the human immune system being more sensitive than the available physical tests or bioassays – the limitations of current analytical methods – the lack of standardized assays • Rare immune-mediated reactions (e.g. 1 in 10,000 patientyears) will only become apparent through robust postmarketing surv ...
Genetics and Heredity
Genetics and Heredity

... mating pair, with offspring listed below. Shaded symbols stand for individuals with the trait being traced. ...
It`s official: high potency ecstasy makes a comeback
It`s official: high potency ecstasy makes a comeback

... ecstasy pills recovered, in 25 separate seizures, contained high levels of MDMA more common in pills made in the 1980s and 1990s. “It is rare these days to get ecstasy pills that contain MDMA, but this year we were surprised because most of the pills did,” Bunt said. The findings back up mounting an ...
DNDi Human African Trypanosomiasis Fact Sheet
DNDi Human African Trypanosomiasis Fact Sheet

... – mandatory for every patient diagnosed. Nifurtimoxeflornithine combination therapy (NECT), developed by Epicentre, MSF, DNDi, and partners for treating stage 2 g-HAT, replaced melarsoprol, a highly toxic arseniccontaining drug which killed 1 in 20 patients. Eflornithine was initially introduced as ...
Medication Reconciliation Review
Medication Reconciliation Review

... Reconciliation is a process of identifying the most accurate list of all medications a patient is taking — including name, dosage, frequency, and route — and using this list to provide correct medications for patients anywhere within the health care system. Reconciliation involves comparing the pati ...
Severe axonal Charcot-Marie-Tooth disease with proximal
Severe axonal Charcot-Marie-Tooth disease with proximal

... muscles (including hip flexors) being weaker than extensor muscles. Clinical presentation is summarized in Table 1. Photographs of the patient are shown in Fig. 1. Nerve conduction studies results are summarized in Table 2. The patient has been tested, since 2001, for PMP22 duplication/deletion and S ...
Mephedrone Information Sheet
Mephedrone Information Sheet

... analysis. At present this analysis would be carried out by forensic teams but plans are being made to re-calibrate EDIT (Evidential Drug Identification Testing) machines and drug itemiser machines to identify this substance – it is unclear if/when this will be done in Thames Valley. The Future Resea ...
Cefoperazone and Sulbactam
Cefoperazone and Sulbactam

... C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients wh ...
FOI 067-1314 document 2 - Therapeutic Goods Administration (TGA)
FOI 067-1314 document 2 - Therapeutic Goods Administration (TGA)

... which 728 patients were treated in long-term comparative trials, against gliclazide 80mg tablets, for up to 1O months. In these comparative trials, the overall incidence and type of adverse events were similar in both DIAMICRON MR and gliclazide 80mg groups. Adverse events were generally mild and tr ...
PowerPoint
PowerPoint

... Stem length (tall or dwarf) ...
Антиепилептични лекарства
Антиепилептични лекарства

... •Diazepam given intravenously or rectally is highly effective for stopping continuous seizure activity, especially generalized tonicclonic status epilepticus. The drug is occasionally given orally on a long-term basis, although it is not considered very effective in this application, probably becaus ...
06 Gout
06 Gout

... With anticancer : 6-mercaptopurine and azathioprine • Allopurinol inhibits • their metabolism •So ,doses of anticancer •Must be reduced up to 75% ...
Cinacalcet for primary hyperparathyroidism
Cinacalcet for primary hyperparathyroidism

... These reduce the half- life of cinacalcet by inducing CYP1A2 enzymes e.g. Smokingclose monitoring of the patient’s smoking status is required and adequate adjustments of cinacalcet carried out. Other Drugs that are known to prolong the QT interval. 8. Adverse drug reactions For a comprehensive list ...
NICE TA 315. Shared Care available
NICE TA 315. Shared Care available

... 4. People currently receiving treatment initiated within the NHS with canagliflozin that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop. ...
SINAREST-LP TABLETS
SINAREST-LP TABLETS

... Do not exceed the recommended dose of 2.5 mg/day in children 6 to 12 years of age. The systemic exposure with the 5 mg dose is approximately twice that of adults. The safety and effectiveness of Sinarest-LP in pediatric patients under 6 years of age have not been established. WARNINGS Sinarest-LP sh ...
KCEMS IM EPI Administration.
KCEMS IM EPI Administration.

... • Approximate onset/duration times IM: 3-5 min/1-4hrs ...
Transdermal Delivery Systems
Transdermal Delivery Systems

... Protective Peel Strip (removed prior to use) ...
Vraylar - Iowa Medicaid PDL
Vraylar - Iowa Medicaid PDL

... There is no pregnancy category with this product; however, the risk summary indicates that neonates exposed to antipsychotic drugs during the 3rd trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There are no data on use in pregnant women to inform ...
Mendel - Powerpoint
Mendel - Powerpoint

... Think of it like a bracelet ◦ This group of bracelets is all of the DNA in one of your cells ◦ One of the bracelets is a chromosome in your cell’s ...
Sponsor vs. Investigator
Sponsor vs. Investigator

... described in the approved labeling.  Off-label therapy with cancer drugs is relatively common in practice. ...
Formulation and Drug Delivery Research Theme flyer
Formulation and Drug Delivery Research Theme flyer

... areas, five representative areas are now described: -The majority of anti-cancer drugs are harmful not only to cancerous cells but also to healthy cells. Anti-cancer drug delivery involves packaging an anti-cancer molecule inside nano-sized carriers which targets the treatment directly to the cancer ...
< 1 ... 938 939 940 941 942 943 944 945 946 ... 1254 >

Pharmacogenomics

Pharmacogenomics (a portmanteau of pharmacology and genomics) is the study of the role of genetics in drug response. It deals with the influence of acquired and inherited genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with drug absorption, distribution, metabolism and elimination, as well as drug receptor target effects. The term pharmacogenomics is often used interchangeably with pharmacogenetics. Although both terms relate to drug response based on genetic influences, pharmacogenetics focuses on single drug-gene interactions, while pharmacogenomics encompasses a more genome-wide association approach, incorporating genomics and epigenetics while dealing with the effects of multiple genes on drug response.Pharmacogenomics aims to develop rational means to optimize drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects. Through the utilization of pharmacogenomics, it is hoped that drug treatments can deviate from what is dubbed as the “one-dose-fits-all” approach. It attempts to eliminate the trial-and-error method of prescribing, allowing physicians to take into consideration their patient’s genes, the functionality of these genes, and how this may affect the efficacy of the patient’s current and/or future treatments (and where applicable, provide an explanation for the failure of past treatments). Such approaches promise the advent of ""personalized medicine""; in which drugs and drug combinations are optimized for each individual's unique genetic makeup. Whether used to explain a patient’s response or lack thereof to a treatment, or act as a predictive tool, it hopes to achieve better treatment outcomes, greater efficacy, minimization of the occurrence of drug toxicities and adverse drug reactions (ADRs). For patients who have lack of therapeutic response to a treatment, alternative therapies can be prescribed that would best suit their requirements. In order to provide pharmacogenomic-based recommendations for a given drug, two possible types of input can be used: genotyping or exome or whole genome sequencing. Sequencing provides many more data points, including detection of mutations that prematurely terminate the synthesized protein (early stop codon).
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report